Skip To Main Content
Davangere Devanand on Muck Rack

Davangere Devanand

As seen in: Nature, Wiley Online Library, Journal of Neurology, Neurosurgery and Psychiatry, The Conversation, The Lancet, Healio, NeurologyLive, Alzheimer's & Dementia
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Davangere

Contact Davangere, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Longitudinal evaluation of neurocognitive outcomes in a cohort with persistent post-COVID olfactory dysfunction

|
By Tiana M Saak, Jeremy P. Tervo, Patricia Jacobson, Brandon J. Vilarello, Francesco Caruana, Liam Gallagher, Joseph Gary, David A. Gudis, Jeffrey N. Motter, Terry E. Goldberg, Davangere Devanand, Jonathan B. Overdevest
| Nature Verified
Abstract Persistent COVID-19-associated olfactory dysfunction (C19OD), along with other neurologic and cognitive deficits are common features of long COVID. This study aims to evaluate longitudinal trends in neurocognitive performance within a cohort with C19OD. In individuals with perceived C19OD we performed serial psychophysical olfactory and neurocognitive assessments at baseline and follow-up one year later.
Open in Who Shared Issue with article?

Characterization of Self‐Administered Olfactory Assessments Novel Olfactory Sorting Task (NOST) and Odor Dilution Sorting (ODS) in a Community‐Based Population

|
By Tiana M Saak, Vagelos College, Renjie Zhang, Davangere Devanand
| Wiley Online Library Verified
Data Availability Statement The original contributions presented in this study are included in the article. Further inquires can be directed to the corresponding author.
Open in Who Shared Issue with article?

Comparison of relative change with effect size metrics in Alzheimer’s disease clinical trials

|
By Terry E. Goldberg, Seonjoo Lee, Davangere Devanand, Lon S Schneider
| Journal of Neurology, Neurosurgery and Psychiatry
Methods The per cent slowing of decline at endpoint is defined as 100×(1−(average decline in treatment group)/(average decline in placebo)) The formula describes a unitless relationship of the difference between groups standardised against the pooled SD using the formula: Cohen’s d=(M1−M2)/√(sd12+sd22)/2, where M=mean and sd=SD deviation of the groups.
Open in Who Shared Issue with article?
See all 12 licensed articles (13 Total)